Conditions: Neoplasm
Keywords: PPARγ agonist advanced or metastatic malignancies Tumor Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 32
Healthy volunteers: no

Brief summary:
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential cohorts of 3 to 6 participants with advanced or metastatic malignancies.

Detailed description:

Arms:
arm 1: CS-7017 from 0.05 to 3.2 mg bid

Interventions: intervention 1: CS-7017
Intervention descriptions: intervention 1: CS-7017 0.05mg and 1.0mg tablets

Protocol document: